Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Rhythm · Phase 3 · Completed · Enrollment 52

NCT03746522

EudraCT 2018-004058-11

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Setmelanotide (Double-Blind)7 participants7 participants2 participantsn/r0
Placebo (Double-Blind)6 participants0 participants1 participantsn/r0
Setmelanotide (Open-label)8 participants8 participants7 participantsn/r0
Pivotal Cohortn/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.